

The lipid-metabolism enzyme ECI2 reduces neutrophil extracellular traps formation for colorectal cancer suppression

Received: 30 August 2023

Accepted: 8 August 2024

Published online: 21 August 2024

 Check for updatesLixia Chen^{1,2,3}, Peiling Dai^{1,2,3}, Lei Liu^{1,2,3}, Yujia Chen^{1,2,3}, Yanxia Lu^{1,2,3}, Lin Zheng^{1,2,3}, Haowei Wang^{1,2,3}, Qinzi Yuan^{1,2,3} & Xuenong Li^{1,2,3} ✉

Abnormalities in ether lipid metabolism as well as the formation of neutrophil extracellular traps have recently been recognized as detrimental factors affecting tumorigenesis and progression. However, the role of abnormal ether lipid metabolism in colorectal cancer (CRC) evolution has not been reported. Here we show that the lipid metabolism-related gene enoyl-CoA δ -isomerase 2 (*ECI2*) plays a tumor-suppressor role in CRC and is negatively associated with poor prognosis in CRC patients. We mechanistically demonstrate that *ECI2* reduces ether lipid-mediated Interleukin 8 (IL-8) expression leading to decreased neutrophil recruitment and neutrophil extracellular traps formation for colorectal cancer suppression. In particular, *ECI2* inhibits ether lipid production in CRC cells by inhibiting the peroxisomal localization of alkyl-glycerone phosphate synthase (AGPS), the rate-limiting enzyme for ether lipid synthesis. These findings not only deepen our understanding of the role of metabolic reprogramming and neutrophil interactions in the progression of CRC, but also provide ideas for identifying potential diagnostic markers and therapeutic targets for CRC.

Tumor metabolic reprogramming plays an important role in CRC, and altered lipid metabolism is considered a hallmark feature of malignancy¹. Lipid metabolic reprogramming is similar to the Warburg effect, with typical features affecting the biology of tumor proliferation, metastasis, and apoptosis¹. It was found that abnormalities in ether lipid metabolism may be closely related to tumor evolution and metastasis². However, there is still a considerable gap in our understanding of the molecular pathways involved in ether lipid metabolism related gene expression and action in CRC.

ECI2 proteins promote the re-entry of enoyl coenzyme A into the β -oxidation cycle³ and also participate in peroxisomal lipid metabolism^{4,5}. There are still relatively few studies on the relevant functions of *ECI* family proteins in tumors⁶. Ether lipids (including alkyl acyl phospholipids and enoyl phospholipids, also known as acetylated phospholipids) are a unique and important class of

glycerophospholipids. Ether lipids contain a glycerol backbone, an alkyl bond, or a vinyl bond, and their alkyl chains are attached to the sn-1 position by an ether bond⁷. Ether lipids are initially synthesized in the peroxisome and processed in the endoplasmic reticulum⁷. Key rate-limiting enzymes involved include *FAR1/2*, *GNPAT*, and *AGPS*⁷. Ether lipids may regulate cell differentiation, influence cell signaling, and reduce oxidative stress through their ability to act as potential endogenous antioxidants^{7–9}. Ether lipids have been found to be increased in a variety of cancers and associated with higher invasiveness¹⁰. Targeted inhibition of peroxisomal lipid metabolic pathways that lead to specific ether lipid production in cancer cells could treat malignancies^{10,11}. Recent studies have identified peroxisome-driven ether lipids as being involved in ferroptosis in cancer¹². *ECI2*, a protein present in both mitochondria and peroxisomes, is thought to be involved in the β -oxidation of

¹Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China. ²Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China. ³Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou, China.

✉ e-mail: nfydxn@126.com

polyunsaturated fatty acids^{4,5}. We wondered whether *ECI2* is aberrantly expressed in CRC and whether it could affect fatty acid oxidation through the CRC. We also wanted to know whether it could regulate peroxisomal ether lipid metabolism.

Neutrophils are increasingly recognized as playing an important role in tumors. One defense response of abnormally triggered neutrophils is known as NETosis, in which activated neutrophils expel their DNA and intracellular contents in a meshwork called neutrophil extracellular traps (NETs)¹³. In cancer, NETosis is associated with increased disease progression, metastasis, and complications^{14–16}. Studies have shown that reactive oxygen species (ROS) production is critical for all forms of NETosis¹⁷. NETs formation in solid tumors is dependent on IL-8¹⁸. CXCL8 belongs to the CXC family of classic chemokines and is responsible for neutrophil recruitment and activation to sites of inflammation^{19,20}. The CXCL8-CXCR1/2 axis plays an important role in tumor growth, angiogenesis, metastasis, stemness, and recruitment of immune cells to the tumor microenvironment^{21,22}. Overexpression of CXCL8 has been observed in a variety of cancers^{20,23}, including colorectal cancer²³. Lipids were found to regulate IL-8 transcription in endothelial cells²⁴. Ether lipids regulate inflammation by maintaining neutrophil membrane phospholipid composition and viability²⁵. Ether glycerol lipids promote Interleukin 1 β (IL-1 β) release and the progression of experimental autoimmune encephalomyelitis²⁶. Recent studies have suggested that hyperoxidation of ether-linked phospholipids accelerates NETs formation²⁷. We wondered whether ether-bonded phospholipids could regulate NETosis and IL-8 in CRC, and if so, what is the mechanism of regulation?

The relationship between ether lipid metabolism and NETosis in CRC is still unknown, despite relevant studies suggesting that ether lipids regulate NETs formation. In the present study, we found that *ECI2* levels were negatively associated with poor prognosis in clinical CRC patients. Mechanistically, *ECI2* inhibits neutrophil extracellular traps-mediated CRC progression in the tumor microenvironment by regulating ether lipid-mediated IL-8 in CRC cells. Furthermore, we found that *ECI2* inhibits ether lipid production by inhibiting the peroxisomal localization of AGPS, the rate-limiting enzyme for ether lipid synthesis in CRC. Taken together, these findings emphasize an important role between *ECI2*, ether lipid metabolism, IL-8 transcription, and NETosis. These findings not only expand our understanding of the roles of metabolic reprogramming and neutrophil-neutrophil interactions in CRC pathogenesis but also provide ideas for finding potential diagnostic markers and therapeutic targets for CRC.

Results

ECI2 downregulation predicts poor prognosis in CRC

We first downloaded the colorectal cancer dataset (Supplementary Data 1) from the TCGA database and analyzed it by GO analysis and KEGG analysis using the Metascape database. The fatty acid metabolic pathway genes enriched in the Reactome gene set in the GO form were analyzed (Supplementary Fig. 1a). Genes differentially expressed in colorectal cancer were screened by GEPIA database. Our aim was to screen for differential genes that are closely related to lipid metabolism in colorectal cancer. Three genes, *FASN*, *PTGS1*, and *SCD*, which were more studied among the first 15 most significantly differentiated genes, were excluded, and the remaining 12 differentially differentiated genes were subjected to RT-qPCR to detect their mRNA levels in 12 pairs of paired colorectal cancer tissues (Supplementary Data 1). The gene *ECI2* was screened to be significantly differentially expressed in this pathway. *ECI2* was found to be differentially expressed in most tumors and normal tissues by the GEPIA database and the Kaplan–Meier database (Supplementary Fig. 1b). The expression of *ECI2* in CRC was significantly lower than that in normal tissues, and the expression of *ECI2* was negatively correlated with the prognosis of


patients with CRC (Supplementary Fig. 1c–e). Application of RT-qPCR and Western blots revealed that *ECI2* expression in CRC cells was lower than that in normal colorectal epithelial cells FHC (Fig. 1a, b). Immunofluorescence experiments revealed that *ECI2* was expressed in mitochondria and peroxisomes in SW620 cells (Fig. 1c). Application of RT-qPCR and Western blots revealed that the expression of *ECI2* in fresh CRC tissues was significantly lower than that in normal tissues (Fig. 1d, e and Supplementary Data 2). Immunohistochemistry showed that *ECI2* expression in CRC tissues was significantly lower than that in normal tissues (Fig. 1f), and was negatively correlated with CRC metastasis (Fig. 1g) and staging (Fig. 1h). Analysis of the relationship between *ECI2* expression and clinicopathological parameters revealed that the expression level of *ECI2* was negatively correlated with CRC tumor size, TNM stage, lymph node metastasis, and distant metastasis (Supplementary Tables 1 and 2). Survival analysis showed that disease-free survival ($P = 0.011$) and overall survival ($P = 0.044$) were higher in colorectal cancer patients with high expression of *ECI2* than in those with low expression of *ECI2* (Fig. 1i, j). The above results suggest that *ECI2* has an inhibitory effect on colorectal cancer growth and metastasis.

ECI2 inhibits CRC invasion and metastasis through tumor cancer microenvironment

Based on the results of *ECI2* expression in CRC cells (Fig. 1a, b), stable overexpression cell lines of *ECI2* were constructed by screening HCT116 and RKO, which expressed *ECI2* at a low level, and stable silencing cell lines of *ECI2* were constructed by screening DLD1 and SW620, which expressed *ECI2* at a high level (Supplementary Fig. 1f, g and Fig. 2a, b). In vitro functional experiments showed that *ECI2* had insignificant effects on the proliferation and invasion of CRC cells. (Fig. 2c–g and Supplementary Fig. 1h–l). Subcutaneous tumor models showed that stable upregulation of *ECI2* significantly inhibited *mouse* colorectal cancer cell line MC38 growth in mice in vivo (Supplementary Fig. 1m–q), while silencing *ECI2* did the opposite (Fig. 2h–k). A significant increase in liver metastatic nodules was observed after further intrasplenic injection of MC38 cells with silenced *ECI2* (Fig. 2l, m). The marked difference between the results of the in vivo and in vitro experiments suggests that *ECI2* may have an effect on the proliferation and metastasis of CRC cells through the tumor microenvironment.

ECI2 inhibits IL-8 expression, neutrophil infiltration and NETosis in CRC

To explore the molecular mechanisms by which *ECI2* inhibits CRC progression, we performed RNA-seq, GO analysis, and KEGG enrichment analysis. The pathway with the highest enrichment score was found to be the downregulated cytokine-cytokine receptor interaction pathway (Fig. 3a and Supplementary Fig. 2a). The genes of this pathway were mapped as heatmaps (Fig. 3b). RT-qPCR experiments on the 12 most significantly changed differential genes showed that *ECI2* overexpression resulted in the most pronounced downregulation of *CXCL8* (IL-8), followed by *CCL5* and *IL15* (Supplementary Fig. 2b). ELISA assay for the highly changed cytokines *CXCL8*, *CCL5*, *CSF1*, and *IL15* in CRC cells revealed that *ECI2* downregulated the CRC cell levels of IL-8 (Fig. 3c, d), but did not affect the levels of *CCL5*, *CSF1* and *IL15* (Supplementary Fig. 2c–e). To explore whether this cytokine pathway affects CRC immunomodulation, immunohistochemistry was performed to detect immune cells in 80 CRC tissues. The results revealed that the infiltration of neutrophils was most pronounced in CRC tissues with low expression of *ECI2* (Supplementary Fig. 2f), and the number of neutrophils infiltrated was negatively correlated with the expression of *ECI2* (Supplementary Fig. 2g). In vivo experiments revealed an increase in neutrophil infiltration after intrasplenic injection of MC38 cells silencing *ECI2* in mice (Fig. 3e, f). Since IL-8 is not expressed in mice, but *CXCL1/KC*, *CXCL2/MIP-2*, and *CXCL5-6/LIX* are thought to be



functional IL-8 homologs²⁸. RT-qPCR examination of the mRNA content of *CXCL1*, 2, and 5 in MC38 silenced with *ECI2* revealed that *CXCL1* was upregulated the most significantly (Supplementary Fig. 2h). We subsequently performed in vivo mouse studies using CXCL1 as a homologue of mouse IL-8. Immunohistochemical examination of mouse liver tissues after intrasplenic injection of MC38 cells that silenced *ECI2* revealed that silencing *ECI2* promoted CXCL1 production in mouse liver metastatic tissues (Fig. 3e). The above in vivo and in vitro functional experiments and RNA-seq results further suggested that

ECI2 may exert an oncogenic role in CRC by affecting neutrophil infiltration and cytokine IL-8.

Because human neutrophils begin to undergo apoptosis within 6 to 12 h of isolation, making their use in experimental studies limited by their very short lifespan²⁹. The human myeloid neutrophil-like cell line, HL-60 cell line, is commonly used as a replacement for human neutrophils, and the gene expression of its differentiated cells bears a resemblance to that of the primary neutrophil³⁰. HL-60 was differentiated into neutrophils with 1.25% DMSO in 5% CO₂ at 37 °C

Fig. 1 | *ECI2* is downregulated in CRC and predicts poor prognosis. RT-qPCR (a) (Representative data from $n = 3$ independent experiments, $P < 0.0001$) and Western blots (b) experiments to detect *ECI2* in seven CRC cell lines and one normal colorectal epithelial cell (FHC) line. b The samples derive from the same experiment but different gels for *ECI2*, and another for Tubulin were processed in parallel. Tubulin served as loading control (The quantification provided under the blots is for the representative blot from $n = 3$ independent experiments). c *ECI2* distribution in SW620 cells. Mitotracker is a mitochondrial probe and PMP70 is a peroxisomal marker (Representative images from $n = 3$ independent experiments, scale bar 10 μm). RT-qPCR (d) ($n = 16$ human samples per group, $P < 0.0001$) and Western blots (e) ($n = 18$ human samples per group, $P < 0.0001$) experiments to detect *ECI2* in fresh CRC (T) and normal tissues (N). Right panel shows the statistics. The samples derive from the same experiment but different gels for *ECI2*, and another

for Tubulin were processed in parallel (e). Tubulin served as loading control. Representative data from $n = 3$ independent experiments. f Immunohistochemical detection of *ECI2* expression in paired CRC tissues ($n = 210$ pairs human samples, 3 fields assessed per sample). Right panel shows the statistics ($P < 0.0001$). g *ECI2* levels in 24 distant metastatic and 186 non-metastatic patients ($n = 186$ non metastasis group, $n = 24$ metastasis group, $P < 0.0001$). h TNM staging for 107 stage III + IV and 103 stage I + II *ECI2* levels ($n = 103$ stage I + II group, $n = 107$ stage III + IV group, $P < 0.0001$). i, j Kaplan–Meier method for statistical analysis of disease-free survival (i) and overall survival (j) ($n = 152$ low *ECI2* group, $n = 58$ high *ECI2* group). Data are expressed as mean \pm s.d. (a, d, e, f, g, h). Statistical significance was determined by two-tailed Paired *t*-test (d, e), two-tailed unpaired Student's *t*-test (f, g, h), one-way ANOVA with Tukey multiple comparison test (a) or log-rank test (i, j). Source data are provided as source data files.





Fig. 2 | *ECI2* inhibits CRC invasion and metastasis through the tumor cancer microenvironment. Western blots to verify the efficiency of overexpressing (a) and silencing (b) *ECI2*. The samples derive from the same experiment but different gels for *ECI2*, and another for Tubulin were processed in parallel (a, b). Tubulin served as loading control. The quantification provided under the blots is for the representative blot from $n = 3$ independent experiments. CCK8 assay to detect changes in proliferation of *ECI2*-silenced CRC cells DLD1 (c) and SW620 (d) (Representative data from $n = 3$ independent experiments). e Colony formation assay to detect the colonies formed by *ECI2*-silenced CRC cells. Right panel shows the statistics (Representative images from $n = 3$ independent experiments). f Transwell invasion assay to detect the invasion by *ECI2*-silenced CRC cells (scale bar 50 μm). Right panel shows the statistics (Representative images from $n = 3$ independent experiments). g The wound healing assay to detect migration of *ECI2*-silenced CRC cells (scale bar 100 μm). Right panel shows the statistics (Representative images from $n = 3$ independent experiments). h–k Subcutaneous

tumorigenic model of C57BL/6j mice constructed by silencing *ECI2*-silenced MC38 cells (18 days post injection, $n = 6$ mice per group, shNC was the control group). h Photographs of the tumors at the end of the experiment. i Representative pictures of HE staining and ki-67 histochemistry of the tumors (3 fields assessed per sample, scale bar 20 μm). Weight (j) ($P < 0.0001$) and volume (k) of the tumors at the end of the experiment ($n = 6$ mice per group). l, m A mouse CRC liver metastasis model was constructed by intrasplenic injection of the mouse CRC cell line MC38, which silences *ECI2* ($n = 7$ mice per group). l Photographs of liver tissues at the end of the experiments (scale bar 1 cm) and HE staining of liver metastatic tumors (3 fields assessed per sample, scale bar 100 μm). m Quantification of liver metastatic nodules ($n = 7$ mice per group). Data are expressed as mean \pm s.d. (c, d, e, f, g, j, k, m). Statistical significance was determined by two-way ANOVA with Tukey or Sidak's multiple comparison test (c, d, e, f, g, k) or two-tailed unpaired Student's *t*-test (j, m). Source data are provided as source data files.

(differentiated neutrophils were noted as dHL-60). Giemsa staining (Supplementary Fig. 2i) and flow cytometry (Supplementary Fig. 2j) assays showed successful differentiation. *ECI2* significantly inhibited CRC cell proliferation (Fig. 3g and Supplementary Fig. 2k) and invasion

(Fig. 3h and Supplementary Fig. 2l) after co-culturing CRC cells with neutrophil dHL-60 cells. Neutrophil dHL-60 chemotaxis assays showed that conditioned medium (CM) of CRC cells overexpressing *ECI2* significantly inhibited dHL-60 migration (Fig. 3i), while the



opposite was true for conditioned medium silencing *ECI2* (Supplementary Fig. 2m). Immunofluorescence staining (Fig. 3j, k and Supplementary Fig. 2n, o) and Western blots (Fig. 3l) revealed that the NETosis was inhibited when CRC cells overexpressing *ECI2* were co-cultured with dHL-60, and the contrary was true for silencing *ECI2*. Immunofluorescence detection of liver tissues of mice after intrasplenic injection of MC38 cells with silenced *ECI2* revealed that silencing

ECI2 promoted the NETosis in metastatic tumor tissues (Fig. 3m, n). ELISA assay revealed that mice in the silenced *ECI2* group had increased levels of cit-H3 in the serums (Fig. 3o). In mice injected intrasplenicly with MC38 cells that silenced *ECI2* and treated with anti-Ly-6G, decreases in the number of liver metastasis nodules (Fig. 3p, q), neutrophil infiltration (Fig. 3p, r), KC (CXCL1) expression (Fig. 3p), and the content of cit-H3 in the serums and liver metastasis

Fig. 3 | ECI2 inhibits CRC IL-8 expression, neutrophil infiltration and NETosis. **a, b** *ECI2*-overexpressing CRC cells were analyzed via RNA-seq and GO functional analysis; cytokine pathway-enriched genes heatmap shown ($n = 3$ samples (per group) generated after independent generation of cells and processed on different days). **c, d** ELISA was used to measure IL-8 (Representative data from $n = 3$ independent experiments, $P < 0.0001$). **e, f** Immunohistochemistry of Ly6G⁺ neutrophils and KC (CLCX1) in liver metastatic tumors (20 μm scale); neutrophils quantified (**f**). $n = 7$ mice per group, 3 fields assessed per sample. **g, h** *ECI2*-overexpressing CRC cells co-cultured with dHL-60; CCK8 and Transwell assays conducted (50 μm scale, $P < 0.0001$). Representative data from $n = 3$ independent experiments. **i** Conditioned medium (CM) of *ECI2*-overexpressing CRC cells induced dHL-60 chemotaxis. $n = 3$ independent experiments. **j–l** Immunofluorescence (Representative images from $n = 3$ independent experiments, scale bar 200 μm , $P < 0.0001$) and Western blots assays were used to detect NETs after co-culture. **l** The samples derive from the same experiment but different gels for cit-H3, and another for H3 were processed in parallel. H3 served as loading control. The quantification provided under the blots is for the representative blot

from $n = 3$ independent experiments. NETs in liver metastases (**m, n**) (200 μm scale, $n = 7$ mice per group, 3 fields assessed per sample) and mice serum (**o**) ($n = 7$ mice per group); **n** Quantification of Fig. 3m. **p–t** Mice were injected intraperitoneally with MC38 cells that silenced *ECI2* and treated with anti-Ly-6G (IgG was the control, $n = 7$ mice per group). **p** Photos of liver tissue (scale bar 1 cm), HE staining (50 μm scale), and immunohistochemistry of neutrophil (50 μm scale; magnification scale bar 150 nm) and KC (CLCX1) (50 μm scale) (3 fields assessed per sample). **q** Quantification of liver metastatic nodules ($n = 7$ mice per group). **r** Quantification of neutrophils ($n = 7$ mice per group, 3 fields assessed per sample, $P < 0.0001$). **s** ELISA assay for the NETs in mice serum ($P < 0.0001$, $n = 7$ mice per group). **t** Immunofluorescence and quantification (right panel) of NETs in liver metastatic tumors ($n = 7$ mice per group, 3 fields assessed per sample, 200 μm scale, $P < 0.0001$). Data are expressed as mean \pm s.d. (**c, d, f, g, h, i, j, k, n, o, q, r, s, t**). Statistical significance was determined by two-way ANOVA with Tukey or Sidak's multiple comparison test (**c, d, g, i**), one-way ANOVA with Tukey multiple comparison test (**h**), two-tailed unpaired Student's *t* test (**f, j, k, n, o, q, r, s, t**) or Hypergeometric Test (**a**). Source data are provided as source data files.

tissues were observed (Fig. 3s, t). The above experimental results indicated that *ECI2* significantly inhibited IL-8 production, neutrophil infiltration, and NETosis in CRC.

ECI2 inhibits CRC invasion and metastasis by reducing IL-8-mediated NETosis


To explore whether *ECI2* regulates the NETosis in CRC by modulating IL-8, we performed the following experiments. Western blots and immunofluorescence experiments showed when dHL-60 was cultured with a conditioned culture of CRC cells silenced with *ECI2*, the NETosis enhanced by silencing of *ECI2* was reversed by the addition of DNase I, a nuclease capable of degrading NET-DNA (Fig. 4a, b). Whereas, when dHL-60 was cultured with a conditioned culture of CRC cells overexpressing *ECI2*, the NETosis suppressed by overexpressing of *ECI2* was reversed by the addition of PMA (phorbol-12-myristate-13-acetate, a potent inducer of NETosis) (Supplementary Fig. 2p, q). After addition of DNase I to dHL-60 co-cultured with *ECI2*-silenced CRC cells, the promotion of CRC cell proliferation (Fig. 4c) and invasion (Fig. 4d) after silencing of *ECI2* was reversed by addition of DNase I to dHL-60. After addition of PMA to dHL-60 co-cultured with CRC cells overexpressing *ECI2*, the proliferation (Supplementary Fig. 2r), and invasion (Supplementary Fig. 2s) of CRC cells inhibited by overexpression of *ECI2* were reversed by addition of PMA to dHL-60. After intrasplenic injection of MC38 cells silencing *ECI2* in mice treated with DNase I, a decrease in the number of liver metastatic nodules (Fig. 4e, f), and in the content of cit-H3 in serums and liver metastasis tissues of mice were observed (Fig. 4g, h). These results suggest that *ECI2* inhibits CRC progression by suppressing NETosis of neutrophils.

The ability of different doses of IL-8 to induce NETosis in primary human neutrophils was detected by SYTOX Green immunofluorescence staining and MPO-DNA complex. It was found that 100 ng/ml IL-8 induced the strongest NETosis of neutrophils (Supplementary Fig. 3a, b). Next, we will apply 100 ng/ml IL-8 for in vitro experiments. *ECI2* overexpressing CRC cells with addition of recombinant IL-8 cytokines were co-cultured with neutrophil dHL-60 to examine the proliferation and invasion of CRC cells, the migration of dHL-60, and the NETosis of neutrophils. The results showed that the dHL-60 cells migration (Supplementary Fig. 3c), the NETosis (Supplementary Fig. 3d, e), CRC cell proliferation (Supplementary Fig. 3f), and invasion (Supplementary Fig. 3g), which were inhibited by *ECI2* overexpression, were all reversed by the cytokine IL-8. While the addition of anti-IL-8 in *ECI2*-silenced CRC cells were co-cultured with neutrophil dHL-60, the proliferation and invasion of CRC cells, migration of dHL-60, and the NETosis of neutrophils were detected. The results showed that the dHL-60 cell migration (Fig. 4i), the NETosis (Fig. 4j, k), CRC cell proliferation (Fig. 4l) and invasion (Fig. 4m), which were promoted by *ECI2* silencing, were all reversed by anti-IL-8. After intrasplenic

injection of *ECI2*-silenced MC38 cells in mice, a reduction in the number of liver metastatic nodules (Supplementary Fig. 3h, i), neutrophil infiltration (Supplementary Fig. 3h, j), KC (CXCL1) expression (Supplementary Fig. 3h), and cit-H3 content in the serums of the mice and in the liver metastatic tissues (Supplementary Fig. 3k, l) were observed by anti-KC (CXCL1) treatment. Similarly, after intrasplenic injection of MC38 cells with simultaneous silencing of *ECI2* and *CXCL1* in mice, a reduction in the number of liver metastatic nodules (Fig. 4n, o), cit-H3 content in the serums of the mice and in the liver metastatic tissues (Fig. 4p, q) were observed. To exclude whether *ECI2* regulates CRC cell proliferation and invasion via IL-8 in the absence of neutrophils, we added recombinant IL-8 cytokines to CRC cells overexpressing *ECI2* or anti-IL-8 to cells silencing *ECI2* but in the absence of neutrophil dHL-60 co-culture to detect CRC cell proliferation and invasion. It was found that in the absence of neutrophils present, *ECI2* exerted insignificant effects on CRC cell proliferation (Supplementary Fig. 3m, o) and invasion (Supplementary Fig. 3n, p) via IL-8. The above results suggest that *ECI2* inhibits CRC invasion and metastasis by reducing the IL-8-mediated NETosis.

ECI2 inhibits ether lipid metabolism-mediated CRC progression by inhibiting AGPS peroxisome localization

To explore whether the lipid metabolism-related gene *ECI2* regulates lipid metabolism, lipidomic analysis revealed that the 20 lipids with significant changes induced by overexpression of *ECI2* were mainly concentrated in ether phospholipids, with ether-lipid-linked phosphatidylethanolamine (PE-O) and ether-lipid-linked phosphatidylcholine (PC-O) the most obvious ones (Fig. 5a). The ether lipids with the most pronounced differences were further confirmed by plotting the thermograms of ether lipid-linked lipids as PE-O and PC-O (Fig. 5b). *ECI2* has been reported to be involved in the β -oxidation of fatty acids. *ECI2* was found not to affect fatty acid oxidation in CRC cells by fatty acid oxidation kit assay (Supplementary Fig. 4a, b). This result is similar to the metabolomics results (Supplementary Data 3). Addition of ether lipids (18:0-18:1 PE-O) in the absence of neutrophils had no significant effect on CRC cell proliferation and invasion (Supplementary Fig. 3m, n). In contrast, the significant inhibitory effect of *ECI2* overexpression on CRC cells was significantly reversed by the addition of 18:0-18:1 PE-O to *ECI2* overexpressing CRC cells co-cultured with neutrophils (Supplementary Fig. 3f, g). After co-culturing dHL-60 with *ECI2* overexpressing CRC cells treated with 18:0-18:1 PE-O, both the inhibition of NETosis (Fig. 5c, d) and the attenuation of dHL-60 cell migration (Fig. 5e) were reversed. The above results suggest that *ECI2* inhibits ether lipid production. The peroxisome plays a central role in the metabolism of reactive oxygen species, bile acids, and ether lipids. Studies of individual peroxisomal proteins and metabolites support their pro-tumorigenic function². At least three peroxisomal proteins



(Pex3, Pex16, and Pex19) are essential for peroxisomal membrane assembly and peroxisomal membrane protein (PMP) import¹¹. PMP70 is a marker for peroxisomal membranes². To explore the mechanism of ECI2 inhibition of ether lipid production, Western blots detection of peroxisome-related markers revealed that ECI2 did not affect the expression of PEX19, PEX16, and PMP70 (Supplementary Fig. 4c), suggesting that ECI2 did not affect peroxisome biogenesis and abundance. The expression of ether lipid metabolism rate-limiting enzymes *FAR1*, *GNPAT*, and *AGPS* was detected by RT-qPCR (Supplementary Fig. 4d) and Western blots (Supplementary Fig. 4e), and it was found that ECI2 did not affect the changes in their mRNA and protein expression levels. By peroxisome isolation assay and Western blots, it

was found that ECI2 did not affect the distribution of *FAR1* and *GNPAT* in peroxisomes and cytoplasm, but ECI2 affected the distribution of *AGPS* (Fig. 5f, g), which resulted in a significant decrease in peroxisomes and a significant increase in cytoplasm (Fig. 5f, g). Immunofluorescence staining also revealed the inhibitory effect of ECI2 on *AGPS* peroxisomal localization (Supplementary Fig. 4f). The above results indicated that ECI2 inhibited the peroxisome localization of *AGPS*, the ether lipid-mediated NETosis and the proliferation and invasion of CRC cells.

We wanted to understand whether ECI2 affects peroxisome localization of other PTS2-containing proteins. Based on the current literature, we detected other PTS2-containing proteins (*PHYH*, *DEPP*,

Fig. 4 | EC12 inhibits CRC invasion and metastasis by IL-8-mediated NETosis. **a, b** *EC12*-silenced CRC cell medium cultured dHL-60 with DNase I (0.25 μ M). NETs detected by Western blots (The quantification provided under the blots is for the representative blot from $n = 3$ independent experiments) and immunofluorescence (200 μ m scale, representative images from $n = 3$ independent experiments). The samples derive from the same experiment but different gels for cit-H3, and another for H3 were processed in parallel (**a**). H3 served as loading control. **c, d** Co-cultured *EC12*-silenced CRC cells with dHL-60 and DNase I; CCK8 ($P < 0.0001$) and Transwell invasion assays conducted (50 μ m scale). Representative data from $n = 3$ independent experiments. **e–h** Mice injected intrasplenically with *EC12*-silenced MC38 cells and DNase I ($n = 7$ mice per group); liver tissue and HE staining (1 cm and 50 μ m scales, 3 fields assessed per sample); **f** metastatic nodule quantification ($n = 7$ mice per group). **g, h** Serum and tumor cit-H3 levels measured by ELISA ($n = 7$ mice per group) and immunofluorescence (200 μ m scale, $n = 7$ mice per group, 3 fields assessed per sample). **i** Anti-IL-8 (500 ng/ml) treated *EC12*-silenced CRC cell supernatants induced dHL-60 chemotaxis ($n = 3$ independent experiments). **j, k** Co-cultured *EC12*-silenced CRC cells with anti-IL-8 and dHL-60 were analyzed for NETs using Western blots (The quantification provided under the blots is for the

representative blot from $n = 3$ independent experiments) and immunofluorescence (200 μ m scale, representative images from $n = 3$ independent experiments, $P < 0.0001$). The samples derive from the same experiment but different gels for cit-H3, and another for H3 were processed in parallel (**j**). H3 served as loading control. **l, m** Silenced *EC12* CRC cells with anti-IL-8 were added and co-cultured with dHL-60, then CCK8 proliferation and Transwell invasion assays were conducted (50 μ m scale, $P < 0.0001$). Representative data from $n = 3$ independent experiments. **n–q** Mice were intrasplenically injected with MC38 cells that silenced *EC12* and silenced *CXCL1* ($n = 6$ mice per group). **n** Photos of liver tissue and HE staining (1 cm and 50 μ m scales, 3 fields assessed per sample). **o** Quantification of liver metastatic nodules ($n = 6$ mice per group). **p, q** Cit-H3 levels in tumors and serum were measured by immunofluorescence (200 μ m scale, $n = 6$ mice per group, 3 fields assessed per sample) and ELISA ($n = 6$ mice per group) ($P < 0.0001$). Data are expressed as mean \pm s.d. (**b, c, d, f, g, h, i, k, l, m, o, p, q**). Statistical significance was determined by two-way ANOVA with Tukey or Sidak's multiple comparison test (**c, i, l**), one-way ANOVA with Tukey multiple comparison test (**d, m**) or two-tailed unpaired Student's *t*-test (**b, f, g, h, k, o, p, q**). Source data are provided as source data files.

Kichip4, P7BP2) other than AGPS by peroxisome isolation assays³¹. We found that *EC12* did not affect other identified PTS2-containing proteins other than AGPS (Supplementary Fig. 4g). To investigate whether there is a physical interaction between *EC12* and AGPS. And, whether *EC12* disrupts the interaction between AGPS and the PTS2 receptor PEX7. The CO-IP experiments revealed that *EC12* did not physically interact with AGPS (Supplementary Fig. 4h); instead, AGPS interacted with PEX7 (Supplementary Fig. 4i). Furthermore, we found that AGPS binding to PEX7 was reduced in *EC12* overexpressing CRC cells. The opposite was true for silencing *EC12* (Supplementary Fig. 4j). It is suggested that *EC12* selectively inhibits the peroxisomal localization of AGPS, possibly by inhibiting the interaction of AGPS with PEX7. *AGPS* lentiviral vector mutated (*AGPS*-Mu) in the PTS2 sequence (responsible for introducing the relevant proteins into the peroxisome) and control wild-type lentiviral vector (*AGPS*-WT) were constructed (Supplementary Fig. 4k). Simultaneous transfection of silencing *EC12* (*shEC12*) and *AGPS*-WT or *AGPS*-Mu revealed that *AGPS*-Mu in the absence of neutrophils had no obvious effect on CRC cell proliferation and invasion after silencing *EC12* (Supplementary Fig. 4l, m). However, CRC cells co-transfected with both *shEC12* and *AGPS*-Wu viruses were found to significantly reverse the enhancement of CRC cell proliferation and invasion after *EC12* knockdown (Supplementary Fig. 4n, o), the enhancement of NETosis (Supplementary Fig. 4p, q), and the migration of dHL-60 (Supplementary Fig. 4r) induced by *EC12* knockdown, when co-cultured with neutrophil dHL-60. The continued addition of 18:0-18:1 PE-O counteracted the effect of *AGPS*-Mu (Supplementary Fig. 4n–r). After intrasplenic injection of MC38 cells in mice transfected with both *EC12* silencing and *AGPS*-WT or *AGPS*-Mu, a reduction in the number of liver metastatic foci (Fig. 5h, i), neutrophil infiltration (Fig. 5h, j), KC (*CXCL1*) expression (Fig. 5h), and cit-H3 content in serums and liver metastatic tissues of the mice were observed in the *AGPS*-Mu group (Fig. 5k, l). The above results tentatively suggest that *EC12* reduces the production of ether lipids by inhibiting the localization of peroxisomes in AGPS, which in turn inhibits the NETosis of neutrophil and the proliferation and invasion of CRC.


EC12 inhibits NETosis and CRC progression by suppressing ether lipid metabolism-mediated IL-8 transcription

To investigate whether *EC12* regulates IL-8 through ether lipids, addition of 18:0-18:1 PE-O revealed significant upregulation of IL-8 in CRC cells overexpressing *EC12* (Fig. 6a). Transfection of *AGPS*-WT or *AGPS*-Mu in CRC cells silencing *EC12* revealed that *AGPS*-Mu significantly downregulated IL-8 (Fig. 6b). To exclude whether ether lipids regulate neutrophil IL-8 production, addition of ether lipids to dHL-60 cells revealed that ether lipids did not affect the amount of IL-8 (Fig. 6c). To determine whether IL-8 accumulation occurs at the transcriptional

level, CRC cells were pretreated with actinomycin D followed by 18:0-18:1 PE-O. RT-qPCR quantitative analysis showed that actinomycin D almost completely inhibited *IL-8* transcription (85% and 95% inhibition in the control and 18:0-18:1 PE-O groups, respectively) (Fig. 6d). To determine whether the differences in IL-8 post-transcriptional regulation explained the differences in IL-8 kinetics induced by the two groups, CRC cells were treated with 18:0-18:1 PE-O for 3 h prior to actinomycin D treatment and RT-qPCR was performed to detect *IL-8* mRNA at different time points. The results showed that *IL-8* transcripts of the two groups were almost completely degraded at around 1 h (Fig. 6e), indicating that the two groups of *IL-8* mRNA half-life was similar. Application of the luciferase reporter plasmid system with *human* IL-8 promoter -1481 to +44 bp showed that 18:0-18:1 PE-O induced transcriptional activation of the *IL-8* promoter (Fig. 6f). These data suggest that 18:0-18:1 PE-O-induced *IL-8* expression in CRC cells is regulated at the transcriptional level.

After different treatments of *EC12* overexpressing CRC cells in advance, they were co-cultured with dHL-60 cells (with or without PMA) to detect CRC cell invasion and NETosis in dHL-60 cells. The results showed that the inhibitory effect of *EC12* overexpression on CRC cell invasion and NETosis in dHL-60 was reversed by 18:0-18:1 PE-O, and then CRC cell invasion and NETosis in dHL-60 were reversed and reduced again by anti-IL-8, and finally PMA acting on dHL-60 cells reversed the effect of anti-IL-8 (Fig. 6g, i). CRC cells invasion and NETosis of dHL-60 cells were examined after transfection of *EC12* gene-silenced CRC cells (with or without IL-8) with *AGPS*-WT or *AGPS*-Mu and co-culturing with neutrophil dHL-60 (with or without DNase I). The results showed that *AGPS*-Mu reversed the promotional effect of silencing *EC12* on CRC cell invasion and NETosis in dHL-60, the addition of cytokine IL-8 in turn reversed and increased CRC cell invasion and NETosis in dHL-60, and finally DNase I reversed the effect of cytokine IL-8 (Fig. 6h, j). The above results suggest that *EC12* inhibits NETosis by suppressing ether lipid metabolism-mediated *IL-8* transcription, which in turn inhibits CRC progression.

It is known that the receptor for IL-8 and *CXCL1* on neutrophils is CXCR1/2, and in order to show the efficacy of CXCR1/2 receptor antagonists, we applied the CXCR1/2 receptor antagonist, Reparixin, for in vivo experiments to improve the clinical significance of the results of this study. In mice injected intrasplenically with MC38 cells that silenced *EC12* and treated with Reparixin, decreases in the number of liver metastasis nodules (Fig. 6k, l), the content of cit-H3 in the liver metastasis tissues and the serums were observed (Fig. 6m, n). For the rigor of the study, we used primary *human* peripheral blood neutrophils and primary *mouse* bone marrow neutrophils instead of dHL-60 for in vitro experimental studies. CM of CRC cells (transfected with *shEC12* or *AGPS*-Mu/*AGPS*-WT; supplemented with anti-IL-8 or 18:0-18:1



PE-O) were used to culture primary neutrophils (1×10^5 , with or without DNase I), then the purified NETs-DNA were used to culture CRC cells to detect alterations in the invasive and proliferative capacity of CRC cells. Similar to the results of the dHL-60 study, EC12 modulated primary neutrophil NETosis-mediated CRC invasion and proliferation by modulating peroxisome localization of AGPS, ether lipids, and IL-8 in CRC cells (Supplementary Figs. 5a–c, 6a–c). ROS production is known to be critical for all forms of NETosis, and we performed ROS assays after CM of CRC cells cultured under different conditions were used to

culture primary *human* neutrophils. It was found that silencing *EC12* and *AGPS* mutations suppressed ROS levels in neutrophils, whereas supplementation with 18:0-18:1 PE-O reversed the effect of *AGPS*-Mu and finally anti IL-8 counteracted the effect of 18:0-18:1 PE-O (Supplementary Fig. 5d). Unexpectedly, we found that treatment of neutrophils with 18:0-18:1 PE-O alone did not alter neutrophils ROS levels, whereas IL-8 alone increased neutrophil ROS levels (Supplementary Fig. 5d). The results suggest that ether lipids need to affect ROS by affecting IL-8. After culturing primary neutrophils (1×10^5 , with or

Fig. 5 | EC12 suppresses ether lipid synthesis by inhibiting peroxisomal localization of AGPS. **a, b** Lipidomic analysis of the overexpressing *EC12* group (*EC12*) and the control group (NC) ($n = 3$ samples (per group) generated after independent generation of cells and processed on different days). **a** The top 20 lipids with the most pronounced differences among the downregulated lipids were detected. **b** Heatmap of ether-associated lipids. **c, d** After addition of 18:0-18:1 PE-O ($10 \mu\text{g}/\text{ml}$) of CRC cells overexpressing *EC12* co-cultured with dHL-60, NETs formation was detected by applying immunofluorescence (**c**) (scale bar $200 \mu\text{m}$, representative images from $n = 3$ independent experiments) and Western blots (**d**) (The quantification provided under the blots is for the representative blot from $n = 3$ independent experiments). The samples derive from the same experiment but different gels for cit-H3, and another for H3 were processed in parallel (**d**). H3 served as loading control. **e** Addition of supernatants from *EC12* overexpressing CRC cells cultured in 18:0-18:1 PE-O ($10 \mu\text{g}/\text{ml}$) induced chemotaxis assay of dHL-60 cells. $n = 3$ independent experiments. **f, g** Peroxisome isolation assay and Western blots to detect changes in FARI, GNPAT, and AGPS in peroxisome (P) and cytoplasm (C) of CRC cells overexpressing (**f**) and silencing *EC12* (**g**). The samples derive from the same experiment but different gels for AGPS, GAPDH, another for FARI, another for

GNPAT and another for PMP70 were processed in parallel (**f, g**). GAPDH and PMP70 served as loading control. The quantification provided under the blots is for the representative blot from $n = 3$ independent experiments. **h–l** Mice were intrasplenically injected with MC38 cells transfected with sh*EC12* and *AGPS*-WT or *AGPS*-Mu lentivirus ($n = 7$ mice per group). **h** Representative images of liver tissue (scale bar 1 cm , 3 fields assessed per sample), HE staining of liver metastatic tumors (scale bar $50 \mu\text{m}$), Ly6G-labeled neutrophils of liver metastatic tumors (scale bar $50 \mu\text{m}$. Enlarged image scale bar 150 nm), and KC (CLCX1) of liver metastatic tumors (scale bar $50 \mu\text{m}$), respectively, from left to right. **i** Quantification of liver metastatic nodules ($n = 7$ mice per group). **j** Quantification of neutrophils in liver metastatic tumors ($n = 7$ mice per group, 3 fields assessed per sample). **k** ELISA assay for the level of cit-H3 in the serum of mice ($P < 0.0001$, $n = 7$ mice per group). **l** Representative pictures of NETs in liver metastatic tumors by applying immunofluorescence assay ($n = 7$ mice per group, 3 fields assessed per sample, scale bar $200 \mu\text{m}$, $P < 0.0001$). Data are expressed as mean \pm s.d. (**c, e, i, j, k, l**). Statistical significance was determined by two-way ANOVA with Tukey or Sidak's multiple comparison test (**e**) or two-tailed unpaired Student's *t*-test (**c, i, j, k, l**). Source data are provided as source data files.

without DNase I) with CM of CRC cells (transfected with sh*EC12* or *AGPS*-Mu/*AGPS*-WT; supplemented with anti-IL-8 or 18:0-18:1 PE-O), Sytox Green dye staining and MPO-DNA complex assay revealed that, similar to dHL-60 cells, NETosis of primary neutrophils was affected by *EC12*, *AGPS*, ether lipids and IL-8 in CRC cells (Supplementary Figs. 5e, f, 6f, g). In agreement with the *in vitro* and *in vivo* results, we examined *AGPS* distribution in *EC12*-silenced mouse MC38 cells and found that *EC12* silencing promoted peroxide media of *AGPS* in MC38 cells (Supplementary Fig. 6d). Further by ELISA assay, we found that *AGPS* mutation in MC38 cells silenced with *EC12* suppressed the level of CXCL1, while the addition of 18:0-18:1 PE-O counteracted the effect of *AGPS*-Mu (Supplementary Fig. 6e).


Discussion

Altered lipid metabolism is considered a hallmark feature of malignant tumors. Ether lipids², as a specific type of lipid, have received increasing attention for their role in tumors^{2,12}. Recently, a relationship between abnormal ether lipid metabolism in peroxisomes and neutrophil function has been reported^{27,32}. However, whether ether lipid metabolism abnormality plays a role in CRC and its aberrant molecular mechanisms are still largely overlooked. In this study, we screened a lipid metabolism-associated protein, *EC12*, and characterized its function in CRC progression. Mechanistically, we found that *EC12* inhibits NETosis-mediated CRC progression in the microenvironment by suppressing ether lipid production-mediated transcription of IL-8 in colorectal cancer cells. In which *EC12* is inhibiting ether lipid production by inhibiting the peroxisomal localization of the ether lipid metabolism rate-limiting enzyme *AGPS* (Supplementary Fig. 7c).

In order to discover the changes of genes related to abnormal lipid metabolism in CRC, we screened the differential gene *EC12* using public databases. Our study found that *EC12* expression was downregulated in CRC tissues and negatively correlated with poor prognosis in CRC patients. Further *in vivo* functional experiments revealed that *EC12* had insignificant effects on the proliferation and invasion of CRC cells *in vitro*. In contrast, *in vivo* experiments in mice revealed that *EC12* significantly inhibited the proliferation and metastasis of CRC. This suggests that we *EC12* may act by affecting the tumor microenvironment of CRC. Further, we found that *EC12* may play a role through neutrophils in the microenvironment. By co-culturing with neutrophils, the proliferation and invasive of CRC cells were enhanced. Studies of neutrophil infiltration into the tumor microenvironment (TME) have revealed their diversity and plasticity in cancer development³³. Tumor-associated neutrophils (TAN) exert both pro- and anti-cancer roles^{16,34,35}, but the mechanisms are not fully understood. There are a large number of published reports supporting the tumor-promoting role of neutrophils^{16,35}. It has been reported that

neutrophils can undergo a unique form of cell death known as NETosis (the process of NETs formation), which involves the extrusion of their nuclear DNA content and cleaved proteins into the extracellular space in the form of so-called NETs³⁶. NETs are involved in the onset and progression of a wide variety of diseases^{17,35}, but the presence of NETs in patients with cancer has not been extensive and in-depth studies until recently^{14,37}, including colorectal cancer³⁸, breast cancer³⁹, and pancreatic cancer⁴⁰. Recent reports have shown that NETs increase tumor growth by driving mitochondrial homeostasis in tumor cells⁴¹. NETs may also impair tumor cell contact with cytotoxic immune cells, leading to evasion of immunological surveillance⁴². Our study found that *EC12*, through inhibition of the CRC NETs to inhibit the proliferation and metastasis of CRC. The duality of neutrophils in cancer extends to cancer treatments such as radiotherapy, chemotherapy, and immunotherapy⁴³. A recent study elaborated that chemotherapy via IL-1 β triggers NETosis to cause epithelial mesenchymal transition and chemoresistance⁴⁴. However, a recent study by Li et al. demonstrated that a combination of drugs induced NETs via ROS in order to enhance chemotherapeutic efficacy in *PI3KCA*-mutant CRC⁴⁵. These two processes differ in terms of triggering mechanism and downstream effects⁴⁶. In addition, the chemotherapeutic agents used in these studies were different. These findings call into question the conventional wisdom that NETs act primarily as impediments to apoptosis⁴⁷ and provoke thought about what specific conditions and factors influence the actions of NETs. The role that NETs play in cancer may depend on a variety of factors, including the substances used to induce NETs, the type of cells targeted, and the specific kind of NETs⁴⁶. Mutational landscapes of cancer may also modulate different roles of neutrophils in chemotherapeutic response or malignant behavior of tumors^{45,46}. Li et al. used a combination of drugs that specifically induced NETs in *PI3KCA*-mutated CRC, suggesting the presence of a mutational effect⁴⁵.

So, what is the mechanism by which *EC12* affects NETosis. A variety of cytokines have been found to play a role in NETs formation^{39,42,48,49}. For example, NETs formation in solid tumors is partially dependent on IL-8^{18,48}. CXCL8 is produced by various cancer cells and regulates cancer progression in an autocrine manner, and overexpression of CXCL8 has been observed in a variety of cancers^{20,23}. Recently, it has been found that the tumor-secreted protease tissue protease C (CTSC) promotes breast-lung metastasis through pro-activation of neutrophil membrane-bound protease 3 (PR3), which facilitates IL-1 β processing and NF- κ B activation, thereby upregulating IL-6 and CCL3 for neutrophil recruitment and NETs formation³⁹. The secreted protease PRSS35 inhibits hepatocellular carcinoma by disabling CXCL2-mediated NETs⁴⁹. Through transcriptomics, we found that *EC12* could enrich in cytokine and cytokine receptor action pathways, we



speculated whether ECI2 acted through the relevant cytokine action on neutrophils yet. Interestingly, we observed in this study that decreased levels of ECI2 led to an increase in the chemokine CXCL8 (IL-8), resulting in greater accumulation of neutrophils and increased NETs formation in TME.

As a lipid metabolism gene, especially a fatty acid oxidation-related gene^{4,5}, we found that ECI2 did not affect fatty acid oxidation in CRC cells by fatty acid oxidation kit assay. Further, we found that ECI2 overexpression significantly decreased multiple ether phospholipids without affecting fatty acid changes by lipid quantitative histology assay, which was consistent with our results. Ether lipids represent an important group of lipids, and abnormalities in their metabolic processes are associated with immune disorders, inflammation, and cancer³². Targeted inhibition of peroxisomal lipid metabolic pathways

leading to specific ether lipid production in cancer cells can treat malignant tumors^{10,11}. Recent studies have reported the involvement of peroxisome-driven ether lipids in the ferroptosis process in cancer¹². Ether lipids also play a role in the regulation of cytokines. Ether lipids were found to affect IL-1 β release and experimental autoimmune encephalomyelitis²⁶. Increased IL-8 transcription in endothelial cells was also found to be regulated by oxidized phospholipids²⁴. Peroxisome beta-oxidation and ether lipid synthesis control the development and activation of innate and adaptive immune cells³². Ether lipids are autoantigens that stimulate invariant natural killer T cells in the thymus⁸. Acute ether lipid deficiency affects neutrophil function in mice⁵⁰. High oxidation of ether-linked phospholipids accelerates NETs formation²⁷. Ether-linked phospholipids have also been found to be required for mitochondrial reactive oxygen species homeostasis⁵¹.

Fig. 6 | EC12 inhibits NETosis and CRC progression by suppressing ether lipid synthesis-mediated IL-8 transcription. **a** *EC12*-overexpressing CRC cells \pm dHL-60 co-culture treated with 18:0-18:1 PE-O, and ELISA detected IL-8 ($P < 0.0001$). **b** sh*EC12* and *AGPS*-WT or *AGPS*-Mu transfected CRC cells \pm dHL-60 co-culture treated with 18:0-18:1 PE-O had IL-8 levels measured by ELISA ($P < 0.0001$). **c** dHL-60 cells with 18:0-18:1 PE-O were assessed for IL-8 by ELISA. **d** CRC cells pretreated with actinomycin D then 18:0-18:1 PE-O for 3 h were analyzed for *IL-8* by RT-qPCR. **e** CRC cells treated with 18:0-18:1 PE-O for 3 h before actinomycin D were sampled at intervals for *IL-8* by RT-qPCR ($P < 0.0001$). **f** Transfected CRC cells with the *human IL-8* promoter and 18:0-18:1 PE-O had luciferase activity measured ($P < 0.0001$). **g**, **i** *EC12*-overexpressing CRC cells successively treated with 18:0-18:1 PE-O, anti-IL-8 and PMA were co-cultured with dHL-60. NETs and invasion detected by Western blots (The quantification provided under the blots is for the representative blot from $n = 3$ independent experiments) and Transwell (Representative data from $n = 3$ independent experiments, 50 μ m scale, $P < 0.0001$). The samples derive from the same experiment but different gels for cit-H3, and another for H3 were processed in parallel (**g**). H3 served as loading control. **h**, **j** sh*EC12* and *AGPS*-Mu

transfected CRC cells treated with recombinant IL-8 and DNase I were co-cultured with dHL-60. NETs and invasion detected by Western blots (The quantification provided under the blots is for the representative blot from $n = 3$ independent experiments) and Transwell (Representative data from $n = 3$ independent experiments, 50 μ m scale, $P < 0.0001$). The samples derive from the same experiment but different gels for cit-H3, and another for H3 were processed in parallel (**h**). H3 served as loading control. **k–n** Mice with *EC12*-silenced MC38 cells treated with Reparixin ($n = 6$ mice per group) were analyzed for liver tissue (1 cm and 50 μ m scale, 3 fields assessed per sample), quantified metastatic nodules ($P < 0.0001$, $n = 6$ mice per group), tumors NETs by immunofluorescence (200 μ m scale, $n = 6$ mice per group, 3 fields assessed per sample) and serum NETs by ELISA ($n = 6$ mice per group). Data are expressed as mean \pm s.d. (**a**, **b**, **c**, **d**, **e**, **f**, **i**, **j**, **l**, **m**, **n**). Statistical significance was determined by two-way ANOVA with Tukey or Sidak's multiple comparison test (**a**, **b**, **d**, **e**, **f**), one-way ANOVA with Tukey multiple comparison test (**i**, **j**) or two-tailed unpaired Student's *t*-test (**c**, **l**, **m**, **n**). Representative data from $n = 3$ independent experiments (**a–f**). Source data are provided as source data files.

Combined with the literature, we speculated whether EC12 would regulate IL-8 and thus affect NETosis in the microenvironment through ether lipids in the CRC. Consistent with our conjecture, our study found that EC12 inhibits ether lipid production, which in turn regulates IL-8 transcription in CRC cells. Further, EC12 was found to inhibit NETosis-mediated CRC progression in the tumor microenvironment by suppressing IL-8 in CRC cells. Additionally, upon antagonizing IL-8, EC12-influenced ether lipid production did not cause NETosis in neutrophils, which further suggests that EC12-regulated ether lipids are required to influence NETosis via IL-8 in CRC cells.

Since EC12 regulates ether lipid metabolism in CRC cells to regulate NETosis, we wondered by what mechanism EC12 regulates ether lipid metabolism. According to reports, peroxisomes are the main organelles producing ether lipids^{7,12}. So far, FARI/2, GNPAT, and AGPS have been found to be the key rate-limiting enzymes for major ether lipid metabolism^{7,12}. Among them, the sequence near the N-terminus (PTS2) of alkylglycerol phosphate synthase (AGPS) is essential for AGPS to enter into the peroxisome and function⁵². AGPS has been reported to alter the structural balance between signaling lipids to enhance cancer pathogenicity¹⁰. Our findings indicate that EC12 abnormalities in CRC cells do not affect peroxisome biogenesis and abundance; nor do they affect the expression of ether lipid metabolism rate-limiting enzymes FARI, GNPAT, and AGPS; but they inhibit the distribution of AGPS. That is, *EC12* overexpression promotes an increase in AGPS in peroxisomes and a decrease in its distribution in the cytoplasm. We wanted to explore why EC12 selectively inhibits peroxisomal localization of AGPS but no other proteins involved in ether lipid synthesis. It was found that EC12 disrupts the interaction between AGPS and the PTS2 receptor PEX7.

To summarize our findings, EC12 inhibits ether lipid production by inhibiting the peroxisome localization of AGPS in CRC cells. It further inhibits neutrophil extracellular trap-mediated colorectal cancer progression by suppressing ether lipid-mediated transcription of IL-8, which in turn inhibits neutrophil extracellular trap-mediated CRC progression. Thus, our study provides strong evidence that EC12 is associated with NETosis in the tumor microenvironment, expanding our understanding of the mechanisms controlling neutrophil recruitment and activity in the TME. In addition, EC12 was also associated with ether lipid metabolism and IL-8 transcription, which provides ideas about the relationship between tumor metabolic reprogramming and immune regulation.

As a malignant tumor, CRC still faces challenges in precise treatment and prevention of recurrence and metastasis, which leads to high mortality and recurrence rates in patients. Therefore, the identification of reliable biomarkers is an important step in reducing the mortality and recurrence rates of CRC patients. However, the progress of our work remains limited by the complexity and variability of tumor

patients and precision therapy medicine. In this study, we analyzed differential genes related to tumor metabolism and found a strong association between EC12, ether chain phospholipid metabolism, NETosis, and CRC prognosis. By applying CXCR1/2 receptor antagonists in mice also provided clinical implications for this study. The combination of detecting low expression of EC12 in colorectal cancer and high levels of the NETosis markers cit-H3 and ether phospholipids in serum could be of potential value as a potential candidate target for CRC therapeutic strategies.

Methods

Ethics statement

Our study complied with all relevant codes of ethics of Southern Medical University. All animal protocols were approved by the Animal Research Ethics Committee of Southern Medical University and were conducted in accordance with the guidelines for the use of laboratory animals. The collection and use of clinical materials and *human* samples were approved by the Institutional Research Ethics Committee of Nanfang Hospital of Southern Medical University.

Cell culture

The MC38 cell line (C57BL/6j mouse colon adenocarcinoma cells) was cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS. All CRC cell lines were cultured in RPMI 1640 medium with 10% FBS. Neutrophils (primary *human* neutrophils, primary *mouse* bone marrow neutrophils, HL-60) were cultured in Roswell Park Memorial Institute (RPMI)1640 medium (Thermo Scientific, Waltham, MA, USA) with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA).

CCK8, colony formation assay, cell wound healing assay, Transwell invasion assay

For Cell proliferation assay⁵³, 1×10^3 cells seeded in 96-well plates, cultured 24 h, treated with CCK-8, 2 h incubation, read at 450 nm, repeated 3 times. For Colony formation assay⁵³, Cells inoculated in 6-well plates, cultured 2 weeks, fixed with 4% paraformaldehyde, stained with 1% Giemsa, colonies >50 counted, 3 experiments done. For Cell wound healing assay⁵³, 1.2×10^6 cells cultured 24 h, wounded, washed, RPMI 1640, closure at 0, 72 h, images for migration, 3 fields measured. For Transwell invasion assay⁵³, pre-coated Transwell chamber with Matrigel, 2×10^5 cells in serum-free media, 8- μ m pores, 10% FBS attractant, 37 $^{\circ}$ C, 2 days, stained with crystal violet, 5 fields counted. Under different culture conditions, CRC cells (transfected with sh*EC12* or *AGPS*-Mu/*AGPS*-WT; supplemented with 500 ng/ml anti-IL-8, 100 ng/ml recombinant IL-8 cytokine or 10 μ g/ml ether lipid (18:0-18:1 PE-O)) were co-cultured with dH-60 cells (1×10^5 , with or without 25 ng/ml PMA, 0.25 μ g/ml DNase I), and CRC cells were assayed by CCK8 assay and Transwell invasion assay.

Clinical human tissue specimens

The 18 paired colorectal cancer lesions and adjacent non-cancerous clinical tissue samples were obtained from colorectal cancer patients (Supplementary Tables 4). All patients were from the Department of General Surgery, Nanfang Hospital, Southern Medical University. Supplementary Table 1 details the clinicopathologic characteristics, of the 210 CRC patients utilized for IHC testing (Fig. 1f). In order to use these clinical materials for research purposes, we obtained prior written informed consent from the patients and approval from the Institutional Research Ethics Committee of Nanfang Hospital of Southern Medical University.

Immunohistochemistry

Processed with heat, dewaxing, rehydration, antigen repair in citrate buffer, peroxide block, sealed with FBS. Overnight incubation with primary antibody at 4 °C, secondary antibody at 37 °C, DAB, and hematoxylin staining, then observed⁵³.

Co-immunoprecipitation (co-IP) assay, RNA extraction, RT-qPCR, and Western blots analysis

For co-IP assay, 1×10^6 cells cultured, washed with cold PBS, lysed with cold RIPA, scraped, oscillated, centrifuged. Protein G beads removed, target antibody incubated, protein A added, washed, boiled, SDS-PAGE, Western blots analyzed⁵³. For RNA extraction and RT-qPCR⁵³, Trizol extracted RNA; PrimeScript RT synthesized cDNA; RT-qPCR on ABI7500 with SYBR PreMix; GAPDH as control. For Western blots⁵³, proteins separated by SDS-PAGE, transferred to PVDF, blocked, incubated with primary/secondary antibodies, detected by chemiluminescence. RT-qPCR primer sequences are shown in the Supplementary Table 3.

Lentiviral and plasmid transduction and transfection

Silencing ECI2 (shECI2) lentivirus was constructed from Obio Technology Co. (Y18163, GL413NC, Shanghai, China), and **overexpression of ECI2, AGPS wild-type (AGPS-WT), and AGPS mutant (AGPS-Mu) lentivirus was constructed from WZ Biosciences Inc** (Shandong, China). Lentiviral and blank vectors transfected, puromycin selected, protein and mRNA analyzed by RT-qPCR and Western blots⁵³.

Mice

Mice were housed at the animal facility of Southern Medical University. Four-week-old female C57BL/6J and 8-week-old female C57BL/6J were purchased from Guangdong Animal Center, China.

Animal studies

All animals were housed at a suitable temperature (18–23 °C) and humidity (22–50%) under a 12/12-h light/dark cycle. All animals were allowed to eat and drink freely during the experiment. All animal experiments were approved by the Animal Research Ethics Committee of Southern Medical University. For the *mouse* subcutaneous tumorigenic model, each group (NC/ECI2, shNC/shECI2) of MC38 cells (4×10^6) was injected subcutaneously into four-week-old female mice (C57BL/6J; Guangdong Animal Center, China). Tumor volume ($\text{length} \times \text{width}^2 \times 0.5$) was measured every 4 days in mice. The tumor load was less than the maximum diameter (15 mm) approved by the University Animal Research Ethics Committee of Southern Medical University. The experiment was terminated when the tumors appeared about 1.5 mm, and all mice were euthanized by inhalation of carbon dioxide.

For the *mouse* colorectal cancer liver metastasis model, 1×10^6 MC38 shNC or MC38 shECI2 cells were added to 100 μL PBS using a 28G insulin syringe and injected into the spleen of 8-week-old female mice (C57BL/6J; Guangdong Animal Center, China) via a 3 cm midline open abdomen. For the role of AGPS-Mu, MC38 cells transfected with both shECI2 and AGPS-WT or AGPS-Mu were injected into the spleens of 8-week-old female mice (C57BL/6J; Guangdong Animal Center,

China). For the role of *mouse* CXCL1, MC38 cells transfected with both shECI2 and shCXCL1 were injected into the spleens of 8-week-old female mice (C57BL/6J; Guangdong Animal Center, China). For the effect of DNase I, after injection of MC38 shECI2 cells into the spleens of 8-week-old female mice (C57BL/6J; Guangdong Animal Center, China), mice were injected with DNase I (2.5 mg/kg, intraperitoneally, Roche) once a day, and the control group was given PBS. For the effect of anti-KC (CXCL1), after injection of MC38 shECI2 cells into the spleens of 8-week-old female mice (C57BL/6J; Guangdong Animal Center, China), mice were injected twice a week intraperitoneally with anti-KC (CXCL1) (1.2 $\mu\text{g}/\text{kg}$, PeproTech), and isotype control IgG was given to the control group. For the effect of anti-Ly6G, after injection of MC38 shECI2 cells into the spleens of 8-week-old female mice (C57BL/6J; Guangdong Animal Center, China), anti-*mouse* Ly6G (5 mg/kg, EBioscience) was injected intraperitoneally twice a week, and isotype control IgG was given to the control group. For the effect of *mouse* CXCR1/2, after injection of MC38 shECI2 cells into the spleens of 8-week-old female mice (C57BL/6J; Guangdong Animal Center, China), mice were injected every two days until the completion of the study intraperitoneally with CXCR1/2 antagonists Reparixin (15 mg/kg, Selleck). Mice were euthanized 25 days after injection of the cells, when the mice lost 20–25% of their body weight or when the mice developed cachexia. Liver metastases (including the size and number of metastatic cancer nodules on the surface of the liver) were observed by dissection. Whole liver tissues were cut and fixed with 10% neutral formalin, and the number of metastatic foci were counted after paraffin embedding, dehydration, serial tissue sections, and HE staining for light microscopic observation. The infiltration of each immune cell and the expression of KC (CXCL1) in the liver tissue were detected by immunohistochemistry; NETs formation (MPO, cit-H3) was detected by immunofluorescence in the liver tissue; and the level of citrullinated histone 3 (cit-H3), which labels NETs, in the serums of mice was detected by ELISA.

Lipidomic analysis

Lipid metabolite analysis of cell samples was performed by the targeted quantitative lipidomic method by Wuhan Metware Biotechnology Co., Ltd (Wuhan, China). Previously frozen colorectal cancer cells (1×10^7) were homogenized in 1 ml of lipid extract (methyl tert-butyl ether: methanol = 3:1). The samples were stirred for 5 min at 4 °C. Then, 200 μL of deionized water was added to the mixture, followed by centrifugation at $12,000 \times g$ for 10 min at 4 °C. The extract supernatant was dried and redissolved. Metabolites were quantified using an ultra-performance liquid chromatography-electrospray tandem mass spectrometry (UPLC-MS/MS) system (UPLC, ExionLC™AD, <https://sciex.com.cn/>; MS/MS, QTRAP® 6500 +, <https://sciex.com.cn/>). Analysis was accomplished using triple quadrupole mass spectrometry in Multiple Reaction Monitoring (MRM) mode. The software Analyst 1.6.3 was utilized to process the mass spectrometry data. The samples were quality controlled and a total of 834 lipid metabolites were detected.

RNA sequencing and data processing

Total RNA was extracted using Trizol (Life Technologies) according to the manufacturer's instructions, and RNA quality was assayed by both the NanoDrop 2000 spectrophotometer and the Agilent 2100/4200 assay. A total of 3 μg of RNA per sample was used for analysis. Sequencing was sampled from a single replicate. Libraries were constructed using the common library method. After library construction, Qubit 3.0 was used for preliminary quantification, and RT-qPCR was used to accurately quantify the effective concentration of the libraries. RNA-seq was performed by BerryGenomics (Beijing, China) on the Illumina NovaSeq 6000 sequencing platform in PE150 mode. After obtaining the sequencing data, basic data quality control was performed first, and then these high-quality sequences were aligned to the reference genome and analyzed for gene expression level and gene

structure. The reference genome for this project can be downloaded from: Genome Download Link (please use IE browser to open this link).

Enzyme-linked immunosorbent assay (ELISA)

Blood samples obtained from mice by venipuncture and cellular serum samples were aliquoted and stored immediately at -80°C according to our institutional specimen storage protocol. Quantification was performed according to the kit manufacturer's instructions, respectively. The kits for *human* IL-8, *human* CCL5, *human* CSF1, *human* IL15, and *mouse* CXCL1 were purchased from Proteintech (China). The kit for *mouse* Cit-H3 was purchased from Ruixin Bio (China).

Isolation of peroxisomes by gradient centrifugation

2×10^8 cells were collected. Peroxisome extraction buffer (5 mM MOPS, pH 7.65, containing 0.25 M sucrose, 1 mM EDTA, and 0.1% ethanol, protease inhibitor mixture) was added (sigma). The cell suspension was then transferred to a Dounce homogenizer tube and carefully homogenized 25 times on ice using a mortar and pestle B. The tube was centrifuged at $1000 \times g$ for 10 min at 4°C , and the supernatant was transferred and centrifuged at $2000 \times g$ for 10 min at 4°C to obtain a pellet (i.e., mitochondrial layer.). The supernatant was transferred to a new centrifuge tube and centrifuged at $25,000 \times g$ for 20 min. The supernatant (peroxisome-free fraction) was transferred to a new tube and the suspension (precipitate) was the crude peroxisome fraction. Peroxisome extraction buffer was added to the precipitate and centrifuged at $100,000 \times g$ for 1.5 h. The substrate was collected for further analysis in Western blots experiments.

Immunofluorescence detection of NETs

CRC cells (transfected with *shEC12* or *AGPS-Mu/AGPS-WT*; with or without 500 ng/ml anti-IL-8, 100 ng/ml recombinant IL-8 cytokine or 10 $\mu\text{g/ml}$ 18:0-18:1 PE-O) conditioned medium was added to 24-well plates with polylysine-coated Cicle Microsop Cover Glass and incubated with dHL-60 (1×10^5 , with or without 25 ng/ml PMA, 0.25 μM DNase I). NETs of dHL-60 cells were detected after 4 h of incubation.

For cell samples, cells were fixed using 4% paraformaldehyde for 15 min, permeabilized in 0.1% Triton X-100 for 5 min. The cover glasses were then closed in PBS containing 2% bovine serum albumin for 1 h at room temperature. Then the cover glasses were incubated overnight at 4°C in a mixture of the two primary antibodies. The following primary antibodies cit-H3 (anti-rabbit antibody, Abcam), MPO (anti-*mouse* antibody, Immunoway) were used. The next day cover glasses were washed using cold PBS and incubated for 1 h in the dark at room temperature with a mixture of two secondary antibodies produced in different species. The following secondary antibodies were used: anti-rabbit labeled with Alexa Fluor 488 and anti-*mouse* labeled with Alexa Fluor 594. Slides and coverslips were restained using 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) to visualize nuclei. The cover glasses were sealed with a sealer containing an anti-fluorescence quencher. Each sample was examined under a fluorescence microscope and photographed. NETosis was determined to be the percentage of field-of-view positivity for citrullinated histone 3 (cit-H3). For paraffin-embedded tissue samples, sections were made at a thickness of 4 mm. After deparaffinization, antigen repair was performed in a citrate solution in a microwave oven (95°C , 30 min). Then closed in PBS containing 2% bovine serum albumin for 1 h at room temperature. The next steps are similar to the staining of cell samples.

Chemotaxis assay

The dHL-60 cells (1×10^5 cells) were added to the upper chamber added to the Transwell device (Corning, 3402). Conditioned medium of differently treated CRC cells (transfected with *shEC12* or *AGPS-Mu/AGPS-WT*; with or without 500 ng/ml anti-IL-8, 100 ng/ml recombinant IL-8 cytokine or 10 $\mu\text{g/ml}$ 18:0-18:1 PE-O) was added to the lower chamber as a chemoattractant. And after 3.5 h of incubation optical

microscopy was observed to count the number of cells located in the lower chamber of the number of dHL-60.

Induction of dHL-60 cell differentiation

HL-60 (ATCC: CCL-240), a *human* myeloid neutrophil-like cell, was cultured in RPMI-1641 (Sigma, USA) with 20% fetal bovine serum (FBS) and 1% penicillin/streptomycin and maintained in a 5% CO_2 incubator at 37°C . The cells were incubated with 1.25% DMSO in 5% CO_2 at 37°C for 5 days to allow them to differentiate into neutrophils, which were recorded as dHL-60. Differentiation was verified by flow cytometry and Giemsa staining.

Flow cytometry

Pre-differentiated and post-differentiated HL-60 cells (5×10^6 cells) were collected. *Goat* serum was blocked on ice for 30 min, and the cells were incubated with *goat* anti-rat CD11b antibody coupled with Alexa fluor647 dye (BD Biosciences) and *goat* anti-rabbit CD16 antibody coupled with FITC (BD Biosciences) for 30 min at 4°C protected from light. Finally, the cells were resuspended in 100 μl PBS and the cell suspension was transferred to flow cytometry tubes for flow cytometry analysis (CytoFLEX S, Beckman). Analysis was performed using Flow-jo (V10.8.1) software (BD, USA).

Actinomycin D assay

To determine whether IL-8 accumulation occurs at the transcriptional level, CRC cells were pretreated with actinomycin D (2 $\mu\text{g/ml}$; FDBio, China) for 30 min, followed by treatment with 18:0-18:1 PE-O (10 $\mu\text{g/ml}$) for 3 h, and RNA was extracted for RT-qPCR. To determine whether IL-8 post-transcriptional regulation differed in the experimental and control groups, CRC cells were treated with 18:0-18:1 PE-O (10 $\mu\text{g/ml}$) for 3 h prior to actinomycin D (2 $\mu\text{g/ml}$) treatment. RNA was extracted at different time points for RT-qPCR detection of *IL-8* mRNA. *IL-8* mRNA abundance was analyzed with GAPDH as an endogenous control.

Luciferase assay

IL-8 activation was measured using the IL-8-dependent luciferase reporter gene (pGL3-IL8-Luc (-1481 + 44)). All experiments were performed according to the kit instructions (Promega). Cells were inoculated in 96-well plates and cell lysis buffer was transferred to black microtiter plates. Firefly luciferase reaction solution was then added and firefly luciferase activity was measured. The activity was measured after incubation with Renilla luciferase reaction solution.

Neutrophil isolation and NETosis detection

Neutrophils were isolated from adult *human* peripheral blood by density gradient separation using dextran-Ficoll-Paque Premium (GE Healthcare) and from bone marrow of 7–8-wk-old mice using Percoll (GE Healthcare)⁵⁴. Isolated neutrophils were confirmed to be of >95% purity by flow cytometric analysis of staining of neutrophil markers. Unless noted otherwise, neutrophils were cultured in RPMI 1640 medium containing 10% FBS.

For visualization, neutrophils cultured with CM from different CRC cells (transfected with *shEC12* or *AGPS-Mu/AGPS-WT*; with or without 500 ng/ml anti-IL-8, 100 ng/ml recombinant IL-8 cytokine or 10 $\mu\text{g/ml}$ 18:0-18:1 PE-O) were inoculated in 96-well plates for the corresponding incubation, and the cell-impermeable DNA dye Sytox-Green (Thermo Fisher Scientific, 1:10,000) and the cell-permeable DNA dye Hoechst33342 (Thermo Fisher Scientific, 1:1000) were added to the incubation system. At the end of the incubation, the plates were moved directly to a fluorescence microscope for NETs formation visualization. For NETs purification, CM-cultured neutrophil supernatants from different CRC cells were centrifuged at $18,000 \times g$ for 10 min at 4°C . The precipitate was then resuspended in 100 μl cold PBS. For each assay, three independent experiments were performed where each experiment used neutrophils from a different donor.

Measuring MPO-DNA complexes

To quantify NETosis, MPO-DNA complexes were identified using a capture ELISA. 96-well microtiter plates were coated with 5 µg/ml anti-MPO monoclonal antibody (Proteintech, 22225-1-AP) as the capturing antibody (75 µl per well) overnight at 4 °C. After blocking in 1% BSA (125 µl per well), 40 µl of samples together with peroxidase-labeled anti-DNA monoclonal antibody was added (component No.2 of the Cell Death Detection ELISA kit, Roche, 11774425001), incubated at room temperature for 2 h and then washed with PBS three times. The peroxidase substrate (ABTS) (Roche, 11774425001) was added. After incubation at 37 °C in the dark for 40 min, the optical density was measured at 405 nm using a microplate reader.

ROS analysis

Neutrophils were treated with different conditioned medium of CRC cells (transfected with sh*ECI2* or *AGPS*-Mu/*AGPS*-WT; with or without 500 ng/ml anti-IL-8, 100 ng/ml recombinant IL-8 cytokine or 10 µg/ml 18:0-18:1 PE-O) for 2 h. Subsequently, the cells were incubated with 10 mM CM-H₂DCFDA (Yeasen), for 15 min and then washed with pre-chilled PBS, and the fluorescence of each well was monitored at 480 nm excitation and 540 nm emission.

Edu assay

CRC cells were inoculated in 24-well plates and cultured for 24 h prior to administration of the Edu assay kit (Beyotime Biotechnology, China). Subsequently, cells were fixed, permeabilized and stained according to the manufacturer's instructions. Image acquisition and analysis using fluorescence microscopy.

Fatty acid oxidation assay

CRC cells were inoculated in 96-well plates and cultured for 24 h. Subsequently, the cells were subjected to FAO assay according to the manufacturer's instructions (AssayGenie, China). O.D.₄₉₂ readings were measured using a microplate reader.

Statistics and reproducibility

Error lines indicate mean ± SD. Statistical significance was assigned at *P* values of <0.05 and detected by Prism9 (GraphPad software), ImageJ software, or SPSS software Statistics 22 (IBM Corp.). The Shapiro-Wilk test was used to determine the sample distribution type. A two-tailed Student's *t*-test was used to evaluate statistical significance between two groups for normal distribution. For the nonparametric tests, the two-tailed Mann-Whitney test was used to evaluate statistical significance between two groups. For more than two groups, the significance was calculated by the Kruskal-Wallis test or ordinary one-way ANOVA depending on the sample distribution type; a post hoc Tukey test was used to conduct multiple comparisons. For more than two factors, the significance was calculated by the two-way ANOVA; a post hoc Tukey or Sidak's test was used to conduct multiple comparisons. Correlations between *ECI2* expression and immune cells were tested with Pearson correlation. A two-sided χ^2 test was used. Survival curves were plotted using the Kaplan-Meier method. Correlation analysis was performed using Correlation of Ozone correlations. The relationship between *ECI2* expression and clinicopathological characteristics was analyzed using the chi-square test and Pearson correlation. The experiments were not randomized, except that mice were randomly grouped before different treatments. Data collection and analysis were not performed blind to the conditions of the experiments, except for IHC score analysis. Each experiment was repeated at least three times independently. Some studies present the results of a representative experiment chosen from independent experiments, where independent experiments refer to experiments conducted on different days. All data in the article, supplementary Information are available.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The RNA-seq data generated in this study have been deposited in the Sequence Read Archive (SRA) under the accession code [PRJNA999604](https://www.ncbi.nlm.nih.gov/sra/PRJNA999604). The metabolomics data generated in this study have been deposited in the MetaboLights database under the accession code [MTBLS10323](https://www.ebi.ac.uk/metabolomics/MTBLS10323). All data in the article, supplementary Information are available. Source data are provided with this paper.

References

- Chen, D. et al. Lipid metabolism reprogramming in colorectal cancer. *J. Cell. Biochem.* **124**, 3–16 (2022).
- Dahabieh, M. S. et al. Peroxisomes and cancer: the role of a metabolic specialist in a disease of aberrant metabolism. *Biochim. Biophys. Acta Rev. Cancer* **1870**, 103–121 (2018).
- Houten, S. M., Violante, S., Ventura, F. V. & Wanders, R. J. The biochemistry and physiology of mitochondrial fatty acid β -oxidation and its genetic disorders. *Annu. Rev. Physiol.* **78**, 23–44 (2016).
- Fan, J., Li, X., Issop, L., Culty, M. & Papadopoulos, V. ACBD2/*ECI2*-mediated peroxisome-mitochondria interactions in Leydig cell steroid biosynthesis. *Mol. Endocrinol.* **30**, 763–782 (2016).
- Fan, J., Liu, J., Culty, M. & Papadopoulos, V. Acyl-coenzyme A binding domain containing 3 (ACBD3; PAF7; GCP60): an emerging signaling molecule. *Prog. Lipid Res.* **49**, 218–234 (2010).
- Dundr, P. et al. HNF1B, EZH2 and *ECI2* in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study. *Sci. Rep.* **10**, 14365 (2020).
- Dean, J. M. & Lodhi, I. J. Structural and functional roles of ether lipids. *Protein Cell* **9**, 196–206 (2018).
- Facciotti, F. et al. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. *Nat. Immunol.* **13**, 474–480 (2012).
- Hossain, M. S. et al. Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling. *PLoS ONE* **8**, e83508 (2013).
- Benjamin, D. I. et al. Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. *Proc. Natl Acad. Sci. USA* **110**, 14912–14917 (2013).
- Lodhi, I. J. & Semenkovich, C. F. Peroxisomes: a nexus for lipid metabolism and cellular signaling. *Cell Metab.* **19**, 380–392 (2014).
- Zou, Y. et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. *Nature* **585**, 603–608 (2020).
- Ronchetti, L. et al. Neutrophil extracellular traps in cancer: not only catching microbes. *J. Exp. Clin. Cancer Res.* **40**, 231 (2021).
- Cristinziano, L. et al. Neutrophil extracellular traps in cancer. *Semin. Cancer Biol.* **79**, 91–104 (2022).
- Masucci, M. T., Minopoli, M., Del Vecchio, S. & Carriero, M. V. The emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis. *Front. Immunol.* **11**, 1749 (2020).
- Hedrick, C. C. & Malanchi, I. Neutrophils in cancer: heterogeneous and multifaceted. *Nat. Rev. Immunol.* **22**, 173–187 (2022).
- Papayannopoulos, V. Neutrophil extracellular traps in immunity and disease. *Nat. Rev. Immunol.* **18**, 134–147 (2018).
- de Andrea, C. E. et al. Heterogeneous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8. *J. Pathol.* **255**, 190–201 (2021).
- Bakouny, Z. & Choueiri, T. K. IL-8 and cancer prognosis on immunotherapy. *Nat. Med.* **26**, 650–651 (2020).
- Raza, S. et al. Multifaceted role of chemokines in solid tumors: from biology to therapy. *Semin. Cancer Biol.* **86**, 1105–1121 (2022).
- Ha, H., Debnath, B. & Neamati, N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. *Theranostics* **7**, 1543–1588 (2017).

22. Liu, Q. et al. The CXCL8-CXCR1/2 pathways in cancer. *Cytokine Growth Factor Rev.* **31**, 61–71 (2016).
23. Casasanta, M. A. et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. *Sci. Signal.* **13**, eaba9157 (2020).
24. Yeh, M. et al. Increased transcription of IL-8 in endothelial cells is differentially regulated by TNF- α and oxidized phospholipids. *Arterioscler. Thromb. Vasc. Biol.* **21**, 1585–1591 (2001).
25. Lodhi, I. J. et al. Peroxisomal lipid synthesis regulates inflammation by sustaining neutrophil membrane phospholipid composition and viability. *Cell Metab.* **21**, 51–64 (2015).
26. Boomkamp, S. D. et al. Effect of ether glycerol lipids on interleukin-1 β release and experimental autoimmune encephalomyelitis. *Chem. Phys. Lipids* **194**, 2–11 (2016).
27. Yotsumoto, S. et al. Hyperoxidation of ether-linked phospholipids accelerates neutrophil extracellular trap formation. *Sci. Rep.* **7**, 16026 (2017).
28. Hol, J., Wilhelmssen, L. & Haraldsen, G. The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies. *J. Leukoc. Biol.* **87**, 501–508 (2010).
29. Kolaczowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. *Nat. Rev. Immunol.* **13**, 159–175 (2013).
30. Collins, S. J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. *Blood* **70**, 1233–1244 (1987).
31. Kunze, M. The type-2 peroxisomal targeting signal. *Biochim. Biophys. Acta Mol. Cell Res.* **1867**, 118609 (2020).
32. Di Cara, F., Savary, S., Kovacs, W. J., Kim, P. & Rachubinski, R. A. The peroxisome: an up-and-coming organelle in immunometabolism. *Trends Cell Biol.* **33**, 70–86 (2023).
33. Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. *Nat. Rev. Cancer* **20**, 485–503 (2020).
34. Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no more. *Nat. Rev. Cancer* **16**, 431–446 (2016).
35. Xiong, S., Dong, L. & Cheng, L. Neutrophils in cancer carcinogenesis and metastasis. *J. Hematol. Oncol.* **14**, 173 (2021).
36. Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. *Science* **303**, 1532–1535 (2004).
37. Zhang, Y. et al. A signature for pan-cancer prognosis based on neutrophil extracellular traps. *J. Immunother. Cancer* **10**, e004210 (2022).
38. Yang, L. et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. *Nature* **583**, 133–138 (2020).
39. Xiao, Y. et al. Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. *Cancer Cell* **39**, 423–437.e427 (2021).
40. Deng, J. et al. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. *JCI Insight* **6**, e146133 (2021).
41. Yazdani, H. O. et al. Neutrophil extracellular traps drive mitochondrial homeostasis in tumors to augment growth. *Cancer Res.* **79**, 5626–5639 (2019).
42. Teijeira, Á. et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. *Immunity* **52**, 856–871.e858 (2020).
43. Shahzad, M. H. et al. Neutrophil extracellular traps in cancer therapy resistance. *Cancers* **14**, 1359 (2022).
44. Mousset, A. et al. Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF- β activation. *Cancer Cell* **41**, 757–775.e710 (2023).
45. Li, Y. et al. Neutrophil extracellular traps induced by chemotherapy inhibit tumor growth in murine models of colorectal cancer. *J. Clin. Invest.* **134**, e175031 (2024).
46. Mousset, A. & Albregues, J. NETs unleashed: neutrophil extracellular traps boost chemotherapy against colorectal cancer. *J. Clin. Invest.* **134**, e178344 (2024).
47. Cools-Lartigue, J., Spicer, J., Najmeh, S. & Ferri, L. Neutrophil extracellular traps in cancer progression. *Cell. Mol. Life Sci.* **71**, 4179–4194 (2014).
48. Ogawa, R. et al. Loss of SMAD4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via the CXCL1/8-CXCR2 axis. *Clin. Cancer Res.* **25**, 2887–2899 (2019).
49. Wang, T. et al. Secreted protease PRSS35 suppresses hepatocellular carcinoma by disabling CXCL2-mediated neutrophil extracellular traps. *Nat. Commun.* **14**, 1513 (2023).
50. Lodhi, I. J., Link, D. C. & Semenovich, C. F. Acute ether lipid deficiency affects neutrophil biology in mice. *Cell Metab.* **21**, 652–653 (2015).
51. Chen, Z. et al. Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. *Nat. Commun.* **14**, 2194 (2023).
52. Kunze, M. et al. Mechanistic insights into PTS2-mediated peroxisomal protein import: the co-receptor PEX5L drastically increases the interaction strength between the cargo protein and the receptor PEX7. *J. Biol. Chem.* **290**, 4928–4940 (2015).
53. Chen, L. et al. CSRP2 suppresses colorectal cancer progression via p130Cas/Rac1 axis-mediated ERK, PAK, and HIPPO signaling pathways. *Theranostics* **10**, 11063–11079 (2020).
54. Kuang, Y., Parthasarathy, U. & Martinelli, R. Protocol for density gradient neutrophil isolation and flow cytometry-based characterization from human peripheral blood. *STAR Protoc.* **4**, 102497 (2023).

Acknowledgements

This work is supported by the National Natural Science Foundation of China (grant number 82072705, 81874074). Please address all the correspondence and requests for materials to X.L. (nfydln@126.com).

Author contributions

X.L. conceived the study and supervised experiments. L.C. and X.L. designed experiments. L.C., P.D., Y.C., and L.L. performed experiments. L.C. and H.W. analyzed RNA-seq data and lipid metabolomics data. Y.L. and X.L. provided clinical specimens. Y.L., Q.Y., and L.Z. provided constructive advice. X.L. and L.C. wrote the paper. All authors read and approved the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-024-51489-1>.

Correspondence and requests for materials should be addressed to Xuenong Li.

Peer review information *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2024